StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3080% above fair value
$276.32+10.15 (+3.81%)

Close on Nov 4, 2026Market cap $665.90BP/E 41.9Yield 1.86%

Johnson & Johnson SPRAVATO (esketamine) by Quarter

SPRAVATO (esketamine) — International operational growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson SPRAVATO (esketamine): 21.4% in Q3 2026, down 2.4 pts from a year earlier.

Latest, Q3 2026
21.4%
Period ended Sep 30, 2026
Change on a year earlier
-2.4 pts
23.8% in Q3 2025
History
12 quarters
Since Q1 2023
Sources
12
Documents cited below

Where the Q3 2026 figure comes from

“|| Intl | 66 | 53 | 22.7 | 21.4 | 1.3”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSPRAVATO (esketamine) — International operational growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202621.4%-2.4 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202634.7%+23.7 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202628.7%-3.0 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q3 2025Sep 28, 202523.8%-23.6 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202511.0%-66.4 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202531.7%-43.1 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 202412.5%-70.9 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 202447.4%–Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 202477.4%–Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202474.8%+62.8 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 202383.4%–Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q1 2023Apr 2, 202312.0%–Form 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗

Cite this data

StockData. (2026). Johnson & Johnson SPRAVATO (esketamine) (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-spravato-intl-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.

See a number that looks wrong?